Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;53(Suppl 1):1-14.
doi: 10.1007/s15010-025-02553-5. Epub 2025 May 26.

Rapid diagnosis of acute pediatric respiratory infections with Point-of-Care and multiplex molecular testing

Affiliations
Review

Rapid diagnosis of acute pediatric respiratory infections with Point-of-Care and multiplex molecular testing

Jane M Caldwell et al. Infection. 2025 Jun.

Erratum in

Abstract

Acute infections of the respiratory tract are very common in pediatric patients, with an estimated global incidence of 17.2 billion cases in 2019. Accurate and timely diagnosis and treatment of acute respiratory infections can prevent progression to more serious pathologies, especially in the young, elderly, immunocompromised, and other high-risk groups. Due to the significant increase in the number of multiplex molecular tests available, there are now many diagnostic options which generate results within minutes or hours, many of which can be performed at point-of-care or near-patient rather than being sent out to a centralized laboratory. Rapid molecular single- or multiplex testing conducted at point-of-care or near-patient offers the potential to improve timely and accurate diagnosis, decrease inappropriate antibiotic use, decrease reliance on chest radiographs, improve timely antiviral administration, reduce the length of hospital stay, reduce the number of clinical visits, and, ultimately, improve patient outcomes. Optimal use of user-friendly multiplex molecular panels also has the potential to improve regional and global disease surveillance and to fill gaps that exist in our understanding of the epidemiology of respiratory infections. These potential benefits, however, come with limitations. For example, use of multiplex PCR assays is not always a cost effective approach. Despite their potential, there are clinical and/or laboratory circumstances where their use becomes cost prohibitive. Another recognized limitation of multiplex PCR assays is that the pathogen detected may not be the cause of a patient's current symptom complex. Such false positive results may occur because the assays are designed to detect pathogen-specific nucleic acid (which may be residual from a prior illness), rather than replication competent pathogens, or because some pathogens can be present without causing symptomatic infection. Further study is needed to determine optimal use of these tests across different patient groups and settings. Incorporating recommendations for best practice use of multiplex molecular assays into clinical guidelines helps offer a framework for their most appropriate use in the diagnosis of pediatric acute respiratory infections.

Keywords: Acute respiratory infection; COVID-19; disease surveillance; Diagnostic methods; Influenza; Molecular diagnostics; Multiplex testing; Point-of-care; Respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Funding: Funding for this supplement manuscript was provided by QuidelOrtho. Funds were provided to medical education provider Medavera, Inc. for author honoraria, publication costs, and open access fees. QuidelOrtho had no authorship or editorial input for this manuscript. Manuscript Preparation: Medavera provided assistance with preparing and editing the manuscript. Declaration of competing interest: JMC is an employee of Medavera, which received funding to write and publish this supplement. CME has received grant support from Merck, Melinta, and Enanta to their institution (USF) and has received speaker or board advisory honoraria from Astellas, Sanofi, Gilead, and Jansen & Jansen. RB and JBD have no competing interests to disclose.

Similar articles

Cited by

References

    1. Lewinski MA, Alby K, Babady NE, Butler-Wu SM, Bard JD, Greninger AL, et al. Exploring the utility of multiplex infectious disease panel testing for diagnosis of infection in different body sites: A joint report of the association for molecular pathology, American society for microbiology, infectious diseases society of America, and Pan American society for clinical virology. J Mol Diagn. 2023;25(12):857–75. 10.1016/j.jmoldx.2023.08.005. - PMC - PubMed
    1. Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021;37:100986. 10.1016/j.eclinm.2021.100986. - PMC - PubMed
    1. Morris PS. Upper respiratory tract infections (including otitis media). Pediatr Clin North Am. 2009;56(1):101–. 10.1016/j.pcl.2008.10.009. 17, x. - PMC - PubMed
    1. Collaborators GL. Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the global burden of disease study 2019. Lancet Infect Dis. 2022;22(11):1626–47. 10.1016/S1473-3099(22)00510-2. - PMC - PubMed
    1. Jamison DT, Mosley WH. Disease control priorities in developing countries: health policy responses to epidemiological change. Am J Public Health. 1991;81(1):15–22. 10.2105/ajph.81.1.15. - PMC - PubMed

LinkOut - more resources